Nonacog alfa Other names: Recombinant coagulation factor IX

Therapeutic indications

Nonacog alfa is indicated for:

Bleeding in haemophilia B (congenital factor IX deficiency)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Treatment of bleeding in patients with haemophilia B (congenital factor IX deficiency).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of bleeding in haemophilia B (congenital factor IX deficiency)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: BENEFIX Powder and solvent for solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈